Regorafenib is a multikinase inhibitor of tyrosine kinases involved in tumor angiogenesis mechanisms (e.g., PDGFR, FGFRs 1–2, VEGFRs 1–3, TIE2), tumor proliferation (e.g., RET, RAF, KIT), tumor microenvironment, and metastasis processes (VEGFR2–3, PDGFR), approved by the FDA and EMA for the treatment of refractory mCRC. This evidence concerns the gene KDR and neoplasm.